AREDS2 explained: the trial behind every eye formula

Two letters and a number, "AREDS2," show up on more eye-supplement bottles and pages than almost anything else in this category, usually without saying who ran it, who was actually enrolled, or what it found. This guide is the missing context: the trial itself, spelled out, so that any bottle claiming a connection to it, including this one, can be checked against the real study instead of against a marketing summary of it.

We wrote this because TheyaVue's own pages compare its label to AREDS2 repeatedly, and a fair comparison needs the trial explained once, in full, rather than referenced in fragments across a dozen pages.

AREDS2, the second Age-Related Eye Disease Study, was run by the National Eye Institute, part of the National Institutes of Health, the U.S. government's own vision-research agency. It was a large, multi-center, randomized, double-blind, placebo-controlled clinical trial, the same design standard used to approve prescription drugs, not an internet survey or a company-funded pilot study Age-Related et al., 2013.

That matters for reading any claim about it. A trial run by a supplement seller, testing its own formula, carries an obvious incentive to find a positive result. AREDS2 was designed, run and published independently of any single supplement brand, and its results apply to the specific formula tested, not to whichever bottle happens to cite it afterward.

That table is the whole formula. Every AREDS2 participant who stayed on the original AREDS core also took this combination daily, with the trial then randomizing people a second way to test adding lutein and zeaxanthin, adding omega-3 fatty acids, or lowering the zinc dose, on top of that core Age-Related et al., 2013. There is no fifth ingredient, no proprietary blend and no undisclosed amount anywhere in it. Every gram is published, which is the opposite of how most eye-supplement labels, including the one this site reviews, choose to print their own blends.

AREDS2 also tested a second question inside the same trial: was 80 mg of zinc a day, the original AREDS amount, still the right dose, or would a lower amount work just as well with less risk?

A secondary randomization split participants between the standard 80 mg zinc arm and a lower 25 mg arm, both using zinc oxide and paired with 2 mg of copper as cupric oxide Age-Related et al., 2013. Copper is not a side note here: NIH's Office of Dietary Supplements documents that zinc doses in this range can interfere with copper absorption and cause a copper deficiency on their own, which is exactly why AREDS paired zinc with copper from the start National Institutes of Health, 2026. Any eye formula that includes a meaningful zinc dose without copper is missing a safeguard the original trial designers built in deliberately.

AREDS2 is one of the better-run, most useful trials in eye health, precisely because its result is specific: a defined formula, in a defined population, slowing a defined disease by a measured amount. Treat any bottle that borrows its name as making a claim about that same narrow thing, and treat any bottle that implies more, sharper sight, prevention in healthy eyes, or a cure, as making a claim the trial never supports.

What this specific label's numbers add up to against that trial is on the ingredients page and the Supplement Facts page. What a biotin-containing formula like this one can do to a blood test, a separate and unrelated safety topic, is covered on the lab tests guide.